{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:30:10Z","timestamp":1789986610557,"version":"4.0.1"},"reference-count":47,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"collaboration among SetLance srl, Zambon Spa and University of Siena","award":["101073263"],"award-info":[{"award-number":["101073263"]}]},{"name":"Italian NRRP, Tuscany Health Ecosystem SPOKE 7. D.D. n. 1050","award":["101073263"],"award-info":[{"award-number":["101073263"]}]},{"name":"Regione Toscana, Italy, CALL COVID-19","award":["101073263"],"award-info":[{"award-number":["101073263"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>SET-M33 is a synthetic peptide that is being developed as a new antibiotic against major Gram-negative bacteria. Here we report two in vivo studies to assess the toxicity and efficacy of the peptide in a murine model of pulmonary inflammation. First, we present the toxicity study in which SET-M33 was administered to CD-1 mice by snout inhalation exposure for 1 h\/day for 7 days at doses of 5 and 20 mg\/kg\/day. The results showed adverse clinical signs and effects on body weight at the higher dose, as well as some treatment-related histopathology findings (lungs and bronchi, nose\/turbinates, larynx and tracheal bifurcation). On this basis, the no observable adverse effect level (NOAEL) was considered to be 5 mg\/kg\/day. We then report an efficacy study of the peptide in an endotoxin (LPS)-induced pulmonary inflammation model. Intratracheal administration of SET-M33 at 0.5, 2 and 5 mg\/kg significantly inhibited BAL neutrophil cell counts after an LPS challenge. A significant reduction in pro-inflammatory cytokines, KC, MIP-1\u03b1, IP-10, MCP-1 and TNF-\u03b1 was also recorded after SET-M33 administration.<\/jats:p>","DOI":"10.3390\/ijms24097967","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T02:27:56Z","timestamp":1682648876000},"page":"7967","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["In Vivo Efficacy and Toxicity of an Antimicrobial Peptide in a Model of Endotoxin-Induced Pulmonary Inflammation"],"prefix":"10.3390","volume":"24","author":[{"given":"Laura","family":"Cresti","sequence":"first","affiliation":[{"name":"U.O.C. Clinical Pathology, Azienda Ospedaliera Universitaria Senese, Via M. Bracci, 53100 Siena, Italy"},{"name":"Medical Biotechnology Department, University of Siena, Via A Moro 2, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Cappello","sequence":"additional","affiliation":[{"name":"Medical Biotechnology Department, University of Siena, Via A Moro 2, 53100 Siena, Italy"},{"name":"SetLance srl, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Vailati","sequence":"additional","affiliation":[{"name":"Zambon spa, Via A. Meucci 3, 20091 Bresso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Melloni","sequence":"additional","affiliation":[{"name":"Zambon spa, Via A. Meucci 3, 20091 Bresso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8144-7186","authenticated-orcid":false,"given":"Jlenia","family":"Brunetti","sequence":"additional","affiliation":[{"name":"Medical Biotechnology Department, University of Siena, Via A Moro 2, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1027-8482","authenticated-orcid":false,"given":"Chiara","family":"Falciani","sequence":"additional","affiliation":[{"name":"Medical Biotechnology Department, University of Siena, Via A Moro 2, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0738-5746","authenticated-orcid":false,"given":"Luisa","family":"Bracci","sequence":"additional","affiliation":[{"name":"U.O.C. Clinical Pathology, Azienda Ospedaliera Universitaria Senese, Via M. Bracci, 53100 Siena, Italy"},{"name":"Medical Biotechnology Department, University of Siena, Via A Moro 2, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pini","sequence":"additional","affiliation":[{"name":"U.O.C. Clinical Pathology, Azienda Ospedaliera Universitaria Senese, Via M. Bracci, 53100 Siena, Italy"},{"name":"Medical Biotechnology Department, University of Siena, Via A Moro 2, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"106103","DOI":"10.1016\/j.ejps.2021.106103","article-title":"Antimicrobial resistance: Prevalence, economic burden, mechanisms of resistance and strategies to overcome","volume":"170","author":"Pulingam","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.37201\/req\/s03.09.2022","article-title":"Antimicrobial resistance and One Health","volume":"35","author":"Serna","year":"2022","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1021\/acsinfecdis.0c00331","article-title":"Antibiotics special issue: Challenges and opportunities in antibiotic discovery and development","volume":"6","author":"Blaskovich","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41570-021-00313-1","article-title":"Towards the sustainable discovery and development of new antibiotics","volume":"5","author":"Miethke","year":"2021","journal-title":"Nat. Rev. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1021\/acsinfecdis.0c00044","article-title":"The antibacterial research and development pipeline needs urgent solutions","volume":"6","author":"Beyer","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_6","unstructured":"World Health Organization (2022, January 20). WHO Publishes List of Bacteria for Which Now Antibiotics Are Urgently Needed. Available online: https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed."},{"key":"ref_7","unstructured":"World Health Organization (2019). 2019 Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline, World Health Organization."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1021\/acsinfecdis.0c00100","article-title":"On the road to discovering urgently needed antibiotics: So close yet so far away","volume":"6","author":"Kim","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"105276","DOI":"10.1016\/j.phrs.2020.105276","article-title":"The revitalization of antimicrobial peptides in the resistance era","volume":"163","author":"Liu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41573-019-0058-8","article-title":"Antimicrobial host defence peptides: Functions and clinical potential","volume":"19","author":"Mookherjee","year":"2020","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S1473-3099(20)30327-3","article-title":"The value of antimicrobial peptides in the age of resistance","volume":"20","author":"Magana","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Li, X., Zuo, S., Wang, B., Zhang, K., and Wang, Y. (2022). Antimicrobial mechanisms and clinical application prospects of antimicrobial peptides. Molecules, 27.","DOI":"10.3390\/molecules27092675"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Bellotti, D., and Remelli, M. (2022). Lights and shadows on the therapeutic use of antimicrobial peptides. Molecules, 27.","DOI":"10.3390\/molecules27144584"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/jam.15314","article-title":"Antimicrobial peptides (AMPs): A promising class of antimicrobial compounds","volume":"132","author":"Kesmen","year":"2022","journal-title":"J. Appl. Microbiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1080\/07388551.2020.1796576","article-title":"Antimicrobial peptides as therapeutic agents: Opportunities and challenges","volume":"40","author":"Mahlapuu","year":"2020","journal-title":"Crit. Rev. Biotechnol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e24122","DOI":"10.1002\/pep2.24122","article-title":"Antimicrobial peptides under clinical investigation","volume":"111","author":"Koo","year":"2019","journal-title":"Pept. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"616979","DOI":"10.3389\/fmicb.2021.616979","article-title":"Review: Lessons Learned from Clinical Trials Using Antimicrobial Peptides (AMPs)","volume":"12","author":"Dijksteel","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: Current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1021\/acs.jmedchem.7b00318","article-title":"The Current State of Peptide Drug Discovery: Back to the Future?","volume":"61","author":"Henninot","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_20","unstructured":"(2022, November 30). FDA Approved Drugs (FDA (2022) Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products."},{"key":"ref_21","unstructured":"US National Library of Medicine (2022, November 30). Clinical Trials, Available online: www.clinicaltrials.gov\/ct2\/results?recrs5d&age_v5&gndr5&type5Intr&rslt5&phase54&phase50&phase51&phase52&phase53&Search5Apply."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"103464","DOI":"10.1016\/j.drudis.2022.103464","article-title":"Peptide-based drug discovery: Current status and recent advances","volume":"28","author":"Sharma","year":"2023","journal-title":"Drug. Discov. Today"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in peptide drug discovery","volume":"4","author":"Muttenthaler","year":"2021","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"46590","DOI":"10.1074\/jbc.M308615200","article-title":"Synthetic peptides in the form of dendrimers become resistant to protease activity","volume":"278","author":"Bracci","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1747-0285.2007.00487.x","article-title":"Molecular basis of branched peptide resistance to enzyme proteolysis","volume":"69","author":"Falciani","year":"2007","journal-title":"Chem. Biol. Drug. Des."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2174\/138920308785915227","article-title":"Branched peptides as therapeutics. Curr","volume":"9","author":"Pini","year":"2008","journal-title":"Protein Pept. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1096\/fj.09-145474","article-title":"A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo","volume":"24","author":"Pini","year":"2010","journal-title":"FASEB J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"26077","DOI":"10.1038\/srep26077","article-title":"In vitro and in vivo efficacy, toxicity, bio-distribution and resistance selection of a novel antibacterial drug candidate","volume":"6","author":"Brunetti","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"25742","DOI":"10.1074\/jbc.M116.750257","article-title":"Immunomodulatory and Anti-inflammatory Activity in Vitro and in Vivo of a Novel Antimicrobial Candidate","volume":"291","author":"Brunetti","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.bbamem.2017.06.001","article-title":"Investigations into the killing activity of an antimicrobial peptide active against extensively antibiotic-resistant K. pneumoniae and P. aeruginosa","volume":"1859","author":"Brunetti","year":"2017","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijantimicag.2019.05.019","article-title":"Antimicrobial activity of two novel antimicrobial peptides AA139 and SET-M33 against clinically and genotypically diverse Klebsiella pneumoniae isolates with differing antibiotic resistance profiles","volume":"54","author":"Boers","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Brunetti, J., Carnicelli, V., Ponzi, A., Di Giulio, A., Lizzi, A.R., Cristiano, L., Cresti, L., Cappello, G., Pollini, S., and Mosconi, L. (2020). Antibacterial and anti-inflammatory activity of an antimicrobial peptide aynthesized with D amino acids. Antibiotics, 9.","DOI":"10.3390\/antibiotics9120840"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1096\/fj.201901896RR","article-title":"An antimicrobial molecule mitigates signs of sepsis in vivo and eradicates infections from lung tissue","volume":"34","author":"Quercini","year":"2020","journal-title":"FASEB J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00726-014-1686-2","article-title":"Site-specific pegylation of an antimicrobial peptide increases resistance to Pseudomonas aeruginosa elastase","volume":"46","author":"Falciani","year":"2014","journal-title":"Amino Acids"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2147\/IJN.S218966","article-title":"Antimicrobial peptide-loaded nanoparticles as inhalation therapy for Pseudomonas aeruginosa infections","volume":"15","author":"Falciani","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Cresti, L., Conte, G., Cappello, G., Brunetti, J., Falciani, C., Bracci, L., Quaglia, F., Ungaro, F., d\u2019Angelo, I., and Pini, A. (2023). Inhalable Polymeric Nanoparticles for Pulmonary Delivery of Antimicrobial Peptide SET-M33: Antibacterial Activity and Toxicity In Vitro and In Vivo. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15010003"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"19294","DOI":"10.1038\/s41598-022-23841-2","article-title":"Safety evaluations of a synthetic antimicrobial peptide administered intravenously in rats and dogs","volume":"12","author":"Cresti","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2165\/00003495-200464140-00006","article-title":"Budesonide\/formoterol: A review of its use in asthma","volume":"64","author":"Goldsmith","year":"2004","journal-title":"Drugs"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M.T., Baker, M., Browne, W.J., Clark, A., Cuthill, I.C., and Dirnagl, U. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol., 18.","DOI":"10.1371\/journal.pbio.3000410"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1080\/08958370802207318","article-title":"Association of Inhalation Toxicologists (AIT) working party recommendation for standard delivered dose calculation and expression in non-clinical aerosol inhalation toxicology studies with pharmaceuticals","volume":"20","author":"Alexander","year":"2008","journal-title":"Inhal. Toxicol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.4155\/bio.15.168","article-title":"Tiered approach into practice: Scientific validation for chromatography-based assays in early development\u2014A recommendation from the European Bioanalysis Forum","volume":"7","author":"Timmerman","year":"2015","journal-title":"Bioanalysis"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0022-5193(63)90004-3","article-title":"Theoretical criteria for the use of relative organ weights and similar ratios in biology","volume":"4","author":"Angervall","year":"1963","journal-title":"J. Theoret. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"220123","DOI":"10.1183\/16000617.0123-2022","article-title":"Severe community-acquired pneumonia","volume":"31","author":"Niederman","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41572-021-00259-0","article-title":"Pneumonia","volume":"7","author":"Torres","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1056\/NEJMra1714562","article-title":"Aspiration pneumonia","volume":"380","author":"Mandell","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e29053","DOI":"10.4161\/cib.29053","article-title":"Lung cell-specific modulation of LPS-induced TLR4 receptor and adaptor localization","volume":"7","author":"Sender","year":"2014","journal-title":"Commun. Integr. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/0192623316642527","article-title":"Characterizing \u201cAdversity\u201d of Pathology Findings in Nonclinical Toxicity Studies: Results from the 4th ESTP International Expert Workshop","volume":"44","author":"Palazzi","year":"2016","journal-title":"Toxicol. Pathol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/9\/7967\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:25:01Z","timestamp":1760124301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/9\/7967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["ijms24097967"],"URL":"https:\/\/doi.org\/10.3390\/ijms24097967","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]}}}